Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV

Executive Summary

Interim Phase IIa data of a triple combination from J&J and Achillion shows 100% SVR at end of treatment with a six-week dosing regimen. No currently approved HCV therapy has such a short treatment duration.

Advertisement

Related Content

With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field
HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates
Gilead Faces Challenges In HCV, But Competitors Would Switch Places
Achillion Data Boosts J&J Combo Potential
Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel